This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2017-04-06 Patient Care FHIR Call"
Jump to navigation
Jump to search
(→Zulip) |
|||
| Line 176: | Line 176: | ||
=== Zulip === | === Zulip === | ||
* [https://chat.fhir.org/#narrow/stream/implementers/subject/Blood.2C.20Tissue.2C.20Organ.3A.20Donation Blood, Tissue, Organ Donation] | * [https://chat.fhir.org/#narrow/stream/implementers/subject/Blood.2C.20Tissue.2C.20Organ.3A.20Donation Blood, Tissue, Organ Donation] | ||
| − | ** NMDP and CIBTMR would like to participate in helping develop a new resource for transplant material | + | ** NMDP (National Marrow Donor Program) and CIBTMR would like to participate in helping develop a new resource for transplant material |
** It would include things like bone marrow, cord blood, peripheral blood stem cells, solid organs, blood transfusion, etc | ** It would include things like bone marrow, cord blood, peripheral blood stem cells, solid organs, blood transfusion, etc | ||
| − | + | ** Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”) | |
* [https://chat.fhir.org/#narrow/stream/implementers/topic/Preferred.20pharmacist CareTeam for Preferred Pharmacist?] | * [https://chat.fhir.org/#narrow/stream/implementers/topic/Preferred.20pharmacist CareTeam for Preferred Pharmacist?] | ||
Revision as of 20:33, 6 April 2017
Contents
Meeting Information
| Patient Care FHIR Resources Conference Call Location: Conference Call |
Date: 2017-04-06 Time: 5-6:30pm ET | ||
| Facilitator | Michelle M Miller | Note taker(s) | Michelle M Miller |
| Attendee | Name | Affiliation
| |
| Elaine Ayres | NIH/Department of Clinical Research Informatics | ||
| Pushpalatha Bhat | |||
| Stephen Chu | The Australian Digital Health Agency (ADHA) | ||
| Evelyn Gallego | EMI Advisors LLC | ||
| Eric Haas | Haas Consulting | ||
| Rob Hausam | Hausam Consulting LLC | ||
| Laura Heermann-Langford | Intermountain Healthcare | ||
| Emma Jones | Allscripts | ||
| Russ Leftwich | InterSystems | ||
| Tony Little | Optum 360 | ||
| Jay Lyle | Ockham Information Services LLC, VA | ||
| Russell McDonell | Telstra Health | ||
| Lloyd McKenzie | Gevity (HL7 Canada) | ||
| Larry McKnight | Cerner | ||
| Michelle M Miller | Cerner | ||
| Lisa Nelson | Life Over Time Solutions | ||
| Viet Nguyen | Lockheed Martin, Systems Made Simple | ||
| M'Lynda Owens | Cognosante | ||
| Craig Parker | Intermountain Healthcare | ||
| Joe Quinn | Optum | ||
| Simon Sum | Academy of Nutrition and Dietetics | ||
| Iona Thraen | Dept of Veterans Affairs | ||
| Serafina Versaggi | Dept of Veterans Affairs | ||
| Bob Milius | NMDP | ||
| Kirt Schaper | CIBMTR | ||
| Quorum Requirements Met: yes | |||
Agenda
Agenda Topics
- Agenda review
- Approve previous meeting minutes 2017-03-23_Patient_Care_FHIR_Call
- Motion: <moved>/<seconded>
- Zulip topics
- Prior Action Item Follow-up
- gForge change request
Supporting Information
- Tracker Issues - https://docs.google.com/a/lmckenzie.com/uc?id=0B285oCHDUr09Mzh3b09rMFhEV1E
- Resolve QA Warnings to have resource FMM > 0
- Resolve QA Information messages to achieve FMM = 3
- Maintain QA checklist
Minutes
Zulip
- Blood, Tissue, Organ Donation
- NMDP (National Marrow Donor Program) and CIBTMR would like to participate in helping develop a new resource for transplant material
- It would include things like bone marrow, cord blood, peripheral blood stem cells, solid organs, blood transfusion, etc
- Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”)
- CareTeam for Preferred Pharmacist?
Prior Action Items
GF#13004 extension-condition-criticality needs a binding to a value set
gForge Change Requests
Adjourn
Adjourned at <hh:mm am/pm> <timezone>.
Meeting Outcomes
| Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2012 Health Level Seven® International. All rights reserved.
